Originally posted by paulk
View Post
Seqanswers Leaderboard Ad
Collapse
Announcement
Collapse
No announcement yet.
X
-
-
Originally posted by TonyBrooks View PostThe problem is that scaffold runs for de novo are so niche in the grand scheme of things.
I wonder what updates will come out next week at AGBT...
Leave a comment:
-
Originally posted by seqnextgen View PostJust a quick reminder of some facts. For ONT to be next PacBio, at least they need to show some data and publish papers in NEJM from sample to print within weeks, not once, but twice. And, they will also need to publish DNA sequencing data/DNA modification data in Nature / Nature Biotech to show important biological results that can not be resolved by 2nd gen. sequencing / Sanger sequencing, etc. (Not just nucleotide identification. DNA sequencing is not about identifying bases/short segments. DNA sequencing should be about efficiently linking long range information...) Commercially successfully or not, the publications and real data already help to reveal some new biology. Until nanopore is no longer nanovapor, there is no fair comparison.
Leave a comment:
-
Just a quick reminder of some facts. For ONT to be next PacBio, at least they need to show some data and publish papers in NEJM from sample to print within weeks, not once, but twice. And, they will also need to publish DNA sequencing data/DNA modification data in Nature / Nature Biotech to show important biological results that can not be resolved by 2nd gen. sequencing / Sanger sequencing, etc. (Not just nucleotide identification. DNA sequencing is not about identifying bases/short segments. DNA sequencing should be about efficiently linking long range information...) Commercially successfully or not, the publications and real data already help to reveal some new biology. Until nanopore is no longer nanovapor, there is no fair comparison.Last edited by seqnextgen; 11-16-2012, 09:11 PM.
Leave a comment:
-
The grand scheme of things of for-profit sector is targeted resequencing for diagnostic. The only thing ONT are proposing that could be useful to them is the no sample prep at all. And I am having a hard time believing that.
While a $100 disposable cartridge would be nice too, especially to forensic and DTC providers, a Q14 isn't useful for any of them.
I agree with other people prediction that ONT will be the next PacBio. It's noble to claim that they will delay their launch until they get Q30, but they need investors, and the current ones will eventually want to cash in. PacBio was able to hype and overhype for 5 years. How much longer is it going to be for ONT?
Leave a comment:
-
Originally posted by pmiguel View PostThe other major claim is that no library construction (or even DNA purification) is required. That would immediately put these devices in their own league. That makes HiSeqs and Torrents niche instruments.
....
--
Phillip
Leave a comment:
-
The other major claim is that no library construction (or even DNA purification) is required. That would immediately put these devices in their own league. That makes HiSeqs and Torrents niche instruments.
Of course there is the weaselly "sample needs 10 base single stranded leader" statement. Not sure what that means. Like you need a cos site digested with lambda terminase? Or you can just heat your sample a little to melt the terminii?
--
Phillip
Leave a comment:
-
Originally posted by TonyBrooks View PostThe problem is that scaffold runs for de novo are so niche in the grand scheme of things. The real money will be in resequencing, RNA-Seq, ChIP-Seq etc. As a core group, I'd say 99% of things we get asked to do fall into those categories. There's still a long way to go for ONT until it becomes a viable alternative.
Q14 is only really of value when you have a bunch of short read Q30s you can pin to the scaffold.
Leave a comment:
-
Dale's post does have an insightful comment at the bottom. How much of the silence from ONT is because they don't have anything to show and how much is due to their current arbitration with Illumina? Maybe they're just playing it close to the vest?
Leave a comment:
-
Leave a comment:
-
Originally posted by earonesty View PostPacBio reads, at Q8, are still quite useful for scaffolding assemblies. Crazy to hold back data when there are lots of people who could make use of long Q14 reads right now.
Q14 is only really of value when you have a bunch of short read Q30s you can pin to the scaffold.
Leave a comment:
-
If anyone's interested, I wrote up this post after talking with Oxford and several others at ASHG.
Really too bad that there wasn't any firm specifications or pricing.
Dale
Leave a comment:
-
Originally posted by TonyBrooks View PostMaybe ONT have learnt from PacBio's mistakes. Remember the anticlimax when you first saw PacBio data?
Nanopore error rate is around 4% ~Q14, or at least it was 9 months ago.
The problem is we've all been spoilt by Illumina SBS and will see anything with < Q30 (or even Q20). They've gone on record saying they won't release anything until error is <1% (which is probably nearer the acceptable level). How far away from that they are is anyone's guess at the moment.
Leave a comment:
-
I think they could release something and just put a giant red asterisk next to it saying this is only really, really preliminary data, really.
Any data at all would, I think, get people to cut them some slack.
Leave a comment:
Latest Articles
Collapse
-
by seqadmin
The field of epigenetics has traditionally concentrated more on DNA and how changes like methylation and phosphorylation of histones impact gene expression and regulation. However, our increased understanding of RNA modifications and their importance in cellular processes has led to a rise in epitranscriptomics research. “Epitranscriptomics brings together the concepts of epigenetics and gene expression,” explained Adrien Leger, PhD, Principal Research Scientist...-
Channel: Articles
04-22-2024, 07:01 AM -
-
by seqadmin
Proteins are often described as the workhorses of the cell, and identifying their sequences is key to understanding their role in biological processes and disease. Currently, the most common technique used to determine protein sequences is mass spectrometry. While still a valuable tool, mass spectrometry faces several limitations and requires a highly experienced scientist familiar with the equipment to operate it. Additionally, other proteomic methods, like affinity assays, are constrained...-
Channel: Articles
04-04-2024, 04:25 PM -
ad_right_rmr
Collapse
News
Collapse
Topics | Statistics | Last Post | ||
---|---|---|---|---|
Started by seqadmin, Yesterday, 08:47 AM
|
0 responses
12 views
0 likes
|
Last Post
by seqadmin
Yesterday, 08:47 AM
|
||
Started by seqadmin, 04-11-2024, 12:08 PM
|
0 responses
60 views
0 likes
|
Last Post
by seqadmin
04-11-2024, 12:08 PM
|
||
Started by seqadmin, 04-10-2024, 10:19 PM
|
0 responses
60 views
0 likes
|
Last Post
by seqadmin
04-10-2024, 10:19 PM
|
||
Started by seqadmin, 04-10-2024, 09:21 AM
|
0 responses
54 views
0 likes
|
Last Post
by seqadmin
04-10-2024, 09:21 AM
|
Leave a comment: